Armistice Capital reports 9.99% stake in Evogene
Rhea-AI Filing Summary
EVOGENE LTD. Schedule 13G reports that Armistice Capital, LLC and Steven Boyd beneficially own 1,104,906 ordinary shares, representing 9.99% of the class as reported. The filing states Armistice Capital exercises shared voting and dispositive power over these shares pursuant to an Investment Management Agreement. The filing is dated 05/15/2026 and cites a position as of 03/31/2026.
Positive
- None.
Negative
- None.
Insights
Armistice reports a near-10% passive stake in EVOGENE.
Armistice Capital and Steven Boyd report beneficial ownership of 1,104,906 shares or 9.99% under a Schedule 13G. The filing attributes shared voting and dispositive power to Armistice via an Investment Management Agreement with its Master Fund.
Because the filing is a Schedule 13G, it is consistent with a passive or qualifying investor status; subsequent amendments could alter intent or ownership and should be watched in periodic disclosures.
Disclosure aligns with Rule 13d reporting for large passive holdings.
The statement clarifies that Armistice Capital, as manager, may be deemed to beneficially own the Master Fund's shares and that the Master Fund "disclaims beneficial ownership" due to lack of voting/dispositive rights under the Investment Management Agreement. The filing includes a joint filing statement signed 05/15/2026.
Filing mechanics and the 9.99% threshold are important because crossing 10% would change reporting obligations; monitor future amendments for any change in status.
Key Figures
Key Terms
Schedule 13G regulatory
Investment Management Agreement financial
beneficially own regulatory
FAQ
What stake does Armistice Capital report in EVGN?
What is the filing date and the reporting date in the Schedule 13G?
What could change the reporting status of this Schedule 13G?
AI-generated analysis. How Rhea-AI works. Not financial advice.